KIMBERLY WHITBECK-DRAKE: Open Payments
NPI 1639786981 · NEW YORK, NY. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$446 in 23 payments from 10 companies in 2025. Trend: 2023 $338 · 2024 $607 · 2025 $446
Food & beverage: $446
| Company | Payments | Amount |
|---|---|---|
| Novartis Pharmaceuticals Corporation | 5 | $109 |
| Amgen Inc. | 4 | $70 |
| AstraZeneca Pharmaceuticals LP | 3 | $49 |
| ABIOMED | 2 | $44 |
| Edwards Lifesciences Corporation | 1 | $42 |
| Esperion Therapeutics, Inc. | 2 | $33 |
| SCPHARMACEUTICALS INC. | 2 | $33 |
| PFIZER INC. | 2 | $33 |
| Novo Nordisk Inc | 1 | $18 |
| Lilly USA, LLC | 1 | $15 |
Products named: LEQVIO, REPATHA, FARXIGA, PASCAL, NEXLETOL, FUROSCIX, ELIQUIS, Wegovy.
Industry payments across NY — which companies pay providers there.
